The U.S. FDA approved AstraZeneca’s Truqap in combination with abiraterone for PTEN-deficient metastatic prostate cancer, offering a new treatment option for patients with this aggressive disease.

Key Highlights

  • The FDA approved AstraZeneca’s Truqap in combination with abiraterone for PTEN-deficient metastatic prostate cancer, the first therapy of its kind for this patient group.
  • The approval is based on the CAPItello-281 Phase III trial, which showed improved outcomes for patients receiving the combination therapy.
  • PTEN-deficient tumors are found in a significant portion of the 35,000 U.S. patients diagnosed annually with metastatic prostate cancer.
  • Truqap, an AKT inhibitor, extended median radiographic progression-free survival compared to the control group.
  • Side effects of Grade 3 or higher were reported in 67% of patients, with rash and hyperglycemia among the most common.

The U.S.

Food and Drug Administration approved AstraZeneca’s Truqap in combination with abiraterone and prednisone for adults with PTEN-deficient metastatic prostate cancer.

The decision, announced on June 15, 2026, follows results from the CAPItello-281 Phase III trial, which evaluated the therapy in a patient population with few treatment alternatives.

Prostate cancer is a leading cancer diagnosis in men, with over 1.4 million new cases globally each year.

In the U.S., more than 300,000 men are diagnosed annually, resulting in approximately 36,000 deaths.

Metastatic prostate cancer, particularly when PTEN-deficient, is known for its aggressive progression and poor outcomes.

An estimated 35,000 U.S.

patients are diagnosed each year with this subtype, which is linked to dysregulation of key cellular pathways.

The CAPItello-281 trial involved 1,012 participants and demonstrated that patients treated with Truqap plus abiraterone experienced a 19% improvement in outcomes compared to those receiving abiraterone alone.

The median radiographic progression-free survival was 33.2 months for the Truqap group, versus 25.7 months in the control group.

While overall survival data are not yet final, early trends suggest a potential benefit for the combination therapy.

Safety findings were consistent with expectations, with 67% of patients experiencing Grade 3 or higher adverse events, including rash (12.3%) and hyperglycemia (10.3%).

The approval also includes a companion diagnostic test to detect PTEN deficiency in prostate tumors.

This biomarker-based approach reflects the growing focus on precision medicine, where treatments are selected based on genetic characteristics rather than a uniform strategy.

Truqap, an AKT inhibitor, had previously received approval for certain breast cancer cases with specific genetic markers, broadening its potential applications.

Experts suggest the approval may change treatment approaches for PTEN-deficient prostate cancer, a subtype historically associated with rapid progression and limited therapeutic choices.

The drug’s dosing schedule, four days on, three days off, was developed to optimize efficacy while managing side effects, a key consideration in long-term cancer care.

With regulatory submissions underway in other regions, AstraZeneca aims to establish Truqap as a foundational therapy in its oncology portfolio.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.